Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HARRY PAUL ERBA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1508942566
CMS profile
158675
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$157,951.83

92 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $56,144.94 28
Incyte Corporation $39,028.76 21
Novartis Pharmaceuticals Corporation $21,595.01 13
Jazz Pharmaceuticals Inc. $11,745.62 12
Agios Pharmaceuticals, Inc. $8,555.00 9
AbbVie Inc. $7,150.00 3
Astellas Pharma US Inc $5,840.00 1
Takeda Pharmaceuticals U.S.A., Inc. $2,640.00 2
Genentech, Inc. $2,310.00 1
Genentech USA, Inc. $1,980.00 1
Amgen Inc. $962.50 1

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HARRY PAUL ERBA

NPI 1508942566 · CMS profile ID 158675

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508942566?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HARRY PAUL ERBA, NPI 1508942566, CMS profile ID 158675. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508942566?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). HARRY PAUL ERBA, NPI 1508942566, CMS profile ID 158675. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508942566?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
HARRY PAUL ERBA, NPI 1508942566, CMS profile ID 158675, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1508942566?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

92 matching records · $157,951.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 92 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–92 of 92.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Agios Pharmaceuticals, Inc. $1,000.0005/04/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751963911 CMS
Agios Pharmaceuticals, Inc. $1,000.0005/04/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751967437 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,320.0004/28/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747330841 CMS
Novartis Pharmaceuticals Corporation $1,310.0004/03/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725715103 CMS
Novartis Pharmaceuticals Corporation $757.4003/31/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725715097 CMS
Incyte Corporation $251.8003/17/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745805685 CMS
Celgene Corporation $639.6003/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727998689 CMS
Celgene Corporation $520.0003/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727998695 CMS
Celgene Corporation $484.2603/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727998699 CMS
Celgene Corporation $81.9303/04/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727998703 CMS
Novartis Pharmaceuticals Corporation $482.5603/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725715057 CMS
Novartis Pharmaceuticals Corporation $22.0003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725715063 CMS
Novartis Pharmaceuticals Corporation $5,240.0003/03/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725715075 CMS
Novartis Pharmaceuticals Corporation $281.8003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725715093 CMS
Celgene Corporation $5,600.0002/12/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727998691 CMS
Incyte Corporation $6,765.0002/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745805677 CMS
Incyte Corporation $211.3202/04/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745805653 CMS
Incyte Corporation $231.8102/04/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745805657 CMS
Incyte Corporation $584.9802/04/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745805661 CMS
Incyte Corporation $81.0202/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745805667 CMS
Incyte Corporation $22.4302/04/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745805669 CMS
Incyte Corporation $17.0002/04/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745805673 CMS
Celgene Corporation $2,400.0001/30/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727998693 CMS
Jazz Pharmaceuticals Inc. $4,410.0001/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744467841 CMS
Jazz Pharmaceuticals Inc. $4,410.0001/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744469313 CMS
Novartis Pharmaceuticals Corporation $64.3401/28/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725715048 CMS
Novartis Pharmaceuticals Corporation $5,240.0001/28/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725715071 CMS
Novartis Pharmaceuticals Corporation $116.6801/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725715081 CMS
Novartis Pharmaceuticals Corporation $429.4001/28/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725715085 CMS
Celgene Corporation $265.4001/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727998687 CMS
Celgene Corporation $174.4701/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727998697 CMS
Celgene Corporation $154.2801/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727998701 CMS
Jazz Pharmaceuticals Inc. $134.7001/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744467845 CMS
Jazz Pharmaceuticals Inc. $23.3401/24/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744467851 CMS
Jazz Pharmaceuticals Inc. $25.0001/24/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744467853 CMS
Jazz Pharmaceuticals Inc. $70.5501/24/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744467855 CMS
Jazz Pharmaceuticals Inc. $124.3401/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744469317 CMS
Jazz Pharmaceuticals Inc. $23.3401/24/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744469323 CMS
Jazz Pharmaceuticals Inc. $25.0001/24/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744469325 CMS
Jazz Pharmaceuticals Inc. $70.5501/24/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744469327 CMS
Jazz Pharmaceuticals Inc. $1,214.4001/16/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744467839 CMS
Jazz Pharmaceuticals Inc. $1,214.4001/16/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744469311 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $238,290.69 206
PY2020 $157,951.83 92
PY2021 $123,603.20 81
PY2022 $110,217.13 92
PY2023 $140,206.34 103
PY2024 $151,795.91 133
PY2025 $187,022.43 138

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $279,572.24 48
PY2024 Principal investigator $755,401.20 77
PY2023 Principal investigator $268,862.14 53
PY2022 Recipient $1,800.00 1
PY2022 Principal investigator $171,827.19 6
PY2021 Principal investigator $587,393.40 24
PY2020 Recipient $98,454.00 3
PY2020 Principal investigator $820,938.26 16
PY2019 Recipient $87,278.32 5
PY2019 Principal investigator $145,604.67 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $10,996.85 12/31/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176658017
Principal investigator 1 Daiichi Sankyo Inc. $18,000.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317455
Principal investigator 1 Daiichi Sankyo Inc. $4,788.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317457
Principal investigator 1 Daiichi Sankyo Inc. $332.50 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317459
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317461
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317463
Principal investigator 1 Daiichi Sankyo Inc. $4,250.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317465
Principal investigator 1 Daiichi Sankyo Inc. $700.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317467
Principal investigator 1 Daiichi Sankyo Inc. $446.90 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317469
Principal investigator 1 Daiichi Sankyo Inc. $1,244.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317471
Principal investigator 1 Daiichi Sankyo Inc. $1,955.00 12/19/2025 Non-covered Recipient Entity
Duke University
AC220-168 No dispute reported 06/30/2026 1225317473
Principal investigator 1 Sumitomo Pharma America, Inc. $209.83 12/11/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657053
Principal investigator 1 Sumitomo Pharma America, Inc. $24,458.70 12/11/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657057
Principal investigator 1 Sumitomo Pharma America, Inc. $2,197.56 12/11/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657061
Principal investigator 1 Sumitomo Pharma America, Inc. $452.20 12/11/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657063
Principal investigator 1 Sumitomo Pharma America, Inc. $1,453.75 12/11/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657070
Principal investigator 1 Sumitomo Pharma America, Inc. $9,975.00 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656933
Principal investigator 1 Sumitomo Pharma America, Inc. $1,643.69 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656937
Principal investigator 1 Sumitomo Pharma America, Inc. $31,321.30 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656941
Principal investigator 1 Sumitomo Pharma America, Inc. $1,452.35 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656945
Principal investigator 1 Sumitomo Pharma America, Inc. $3,963.20 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176656949
Principal investigator 1 Sumitomo Pharma America, Inc. $21,758.80 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657005
Principal investigator 1 Sumitomo Pharma America, Inc. $1,228.91 12/04/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176657008
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,330.00 12/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250217979
Principal investigator 1 Agios Pharmaceuticals, Inc. $5,051.00 12/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250218239
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,963.00 09/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418335
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,551.00 09/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211420481
Principal investigator 1 TAIHO ONCOLOGY, INC. $5,293.00 09/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211420483
Principal investigator 1 Sumitomo Pharma America, Inc. $1,468.63 07/24/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176641301
Principal investigator 1 Sumitomo Pharma America, Inc. $13,300.00 07/24/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176641305
Principal investigator 1 Sumitomo Pharma America, Inc. $3,232.41 07/17/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176640698
Principal investigator 1 Sumitomo Pharma America, Inc. $16,545.20 07/17/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176640702
Principal investigator 1 TAIHO ONCOLOGY, INC. $226.00 06/20/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419749
Principal investigator 1 Sumitomo Pharma America, Inc. $800.66 06/05/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176636129
Principal investigator 1 Sumitomo Pharma America, Inc. $10,477.50 06/05/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176636133
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 05/09/2025 Non-covered Recipient Entity
DUKE ABMT CLINIC
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176634648
Principal investigator 1 Sumitomo Pharma America, Inc. $3,762.89 04/24/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176633719
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,655.81 04/07/2025 Covered Recipient Teaching Hospital
Duke University Hospital
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) No dispute reported 06/30/2026 1236001294
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,476.00 03/19/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250218057
Principal investigator 1 TAIHO ONCOLOGY, INC. $8,618.00 03/19/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419747
Principal investigator 1 Sumitomo Pharma America, Inc. $1,596.00 02/27/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176628681
Principal investigator 1 Sumitomo Pharma America, Inc. $4,655.00 02/27/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176628689
Principal investigator 1 Sumitomo Pharma America, Inc. $8,857.60 02/27/2025 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176628693
Principal investigator 1 Sumitomo Pharma America, Inc. $46.00 02/27/2025 Non-covered Recipient Entity
DUKE ABMT CLINIC
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176628703
Principal investigator 1 Agios Pharmaceuticals, Inc. $4,825.00 02/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250217142
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,330.00 02/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250217370
Principal investigator 1 Agios Pharmaceuticals, Inc. $3,963.00 02/26/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes No dispute reported 06/30/2026 1250217372
Principal investigator 1 Novartis Pharmaceuticals Corporation $220.00 01/01/2025 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy No dispute reported 06/30/2026 1190305929